[
  {
    "ts": null,
    "headline": "'Declare victory and move on': Eli Lilly CEO on Trump tariff threat",
    "summary": "Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.",
    "url": "https://finnhub.io/api/news?id=2c2e5044bc33af9ac4601d0d887ececd2ba1d64326a151e7e310a973c8dc0dd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746115606,
      "headline": "'Declare victory and move on': Eli Lilly CEO on Trump tariff threat",
      "id": 134173462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.",
      "url": "https://finnhub.io/api/news?id=2c2e5044bc33af9ac4601d0d887ececd2ba1d64326a151e7e310a973c8dc0dd0"
    }
  },
  {
    "ts": null,
    "headline": "Pharma downplays tariff threat, even as risks remains unclear",
    "summary": "Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.",
    "url": "https://finnhub.io/api/news?id=52aa4126406701afb65caf7d50d29c9a2156536dd4d314161cdfa2a046d2ed0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746102240,
      "headline": "Pharma downplays tariff threat, even as risks remains unclear",
      "id": 134184767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.",
      "url": "https://finnhub.io/api/news?id=52aa4126406701afb65caf7d50d29c9a2156536dd4d314161cdfa2a046d2ed0c"
    }
  },
  {
    "ts": null,
    "headline": "If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?",
    "summary": "Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?",
    "url": "https://finnhub.io/api/news?id=428e26366024350974a7d1d16d126d7877e66c039154a1179f8515fe5d3cee4d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746100844,
      "headline": "If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?",
      "id": 134173473,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?",
      "url": "https://finnhub.io/api/news?id=428e26366024350974a7d1d16d126d7877e66c039154a1179f8515fe5d3cee4d"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Value Fund Q1 2025 Commentary",
    "summary": "The challenge of constant and intense debates in the pursuit of better judgment and the surfacing of hidden truth within an always foggy market landscape is worth it.",
    "url": "https://finnhub.io/api/news?id=815603c58a6c60981789c59d688117925b6bf46711f610c0d1b153b4d8eb742b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746099900,
      "headline": "ClearBridge Value Fund Q1 2025 Commentary",
      "id": 134172846,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990349798/image_1990349798.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The challenge of constant and intense debates in the pursuit of better judgment and the surfacing of hidden truth within an always foggy market landscape is worth it.",
      "url": "https://finnhub.io/api/news?id=815603c58a6c60981789c59d688117925b6bf46711f610c0d1b153b4d8eb742b"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Small Cap Growth Fund Q1 2025 Commentary",
    "summary": "Last yearâs pattern of large caps outperforming small caps has continued, although growth leadership has given way to value amid the preference for defense.",
    "url": "https://finnhub.io/api/news?id=23a8bb34c5988131e500abf725d50fe2bf0cc395068a088d36d004a6f9b8dcbe",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746099300,
      "headline": "ClearBridge Small Cap Growth Fund Q1 2025 Commentary",
      "id": 134172821,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1283342758/image_1283342758.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Last yearâs pattern of large caps outperforming small caps has continued, although growth leadership has given way to value amid the preference for defense.",
      "url": "https://finnhub.io/api/news?id=23a8bb34c5988131e500abf725d50fe2bf0cc395068a088d36d004a6f9b8dcbe"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves J&J’s Imaavy for generalised myasthenia gravis",
    "summary": "The approval by the US regulator is based on data from the pivotal Vivacity-MG3 trial.",
    "url": "https://finnhub.io/api/news?id=e07a5b058bafcbe748eb04a434ee41c2d7837f127d73a1ee8f7212e371824028",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746096009,
      "headline": "FDA approves J&J’s Imaavy for generalised myasthenia gravis",
      "id": 134173518,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The approval by the US regulator is based on data from the pivotal Vivacity-MG3 trial.",
      "url": "https://finnhub.io/api/news?id=e07a5b058bafcbe748eb04a434ee41c2d7837f127d73a1ee8f7212e371824028"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis",
    "summary": "Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.",
    "url": "https://finnhub.io/api/news?id=1daf822f8bd8bc3f13ffbce032e8cb0f29276b78556b74df0e12007b2d5c6a75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746089340,
      "headline": "The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis",
      "id": 134173519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.",
      "url": "https://finnhub.io/api/news?id=1daf822f8bd8bc3f13ffbce032e8cb0f29276b78556b74df0e12007b2d5c6a75"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says Tariffs Politically Risky, But He’s Not Rushing Deals",
    "summary": "President Donald Trump acknowledged that his sweeping tariff program had risked imperiling him politically, but said he would not rush deals to appease nervous investors during a town hall on Wednesday.",
    "url": "https://finnhub.io/api/news?id=0e07df59b622c914a13d9e981b2c716c315fd8f8b8eb172f488f7a0502f17eee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746064106,
      "headline": "Trump Says Tariffs Politically Risky, But He’s Not Rushing Deals",
      "id": 134173520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "President Donald Trump acknowledged that his sweeping tariff program had risked imperiling him politically, but said he would not rush deals to appease nervous investors during a town hall on Wednesday.",
      "url": "https://finnhub.io/api/news?id=0e07df59b622c914a13d9e981b2c716c315fd8f8b8eb172f488f7a0502f17eee"
    }
  },
  {
    "ts": null,
    "headline": "Franklin Income Fund Q1 2025 Commentary",
    "summary": "Franklin Income Fund underperformed its benchmark, the Blended 50% MSCI USA High Dividend Yield Index + 25% Bloomberg High Yield Very Liquid Index + 25% Bloomberg US Aggregate Index.",
    "url": "https://finnhub.io/api/news?id=1fbc31454716e9554e0107171c02d09c1922c1510eb20cb23929f39d91657a9a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746063600,
      "headline": "Franklin Income Fund Q1 2025 Commentary",
      "id": 134168520,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397011551/image_1397011551.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Franklin Income Fund underperformed its benchmark, the Blended 50% MSCI USA High Dividend Yield Index + 25% Bloomberg High Yield Very Liquid Index + 25% Bloomberg US Aggregate Index.",
      "url": "https://finnhub.io/api/news?id=1fbc31454716e9554e0107171c02d09c1922c1510eb20cb23929f39d91657a9a"
    }
  }
]